NEW YORK (GenomeWeb) – Claritas Genomics today announced it has secured $15 million in Series B financing.
The Cambridge, Mass.-based pediatric genetic testing services firm said that the funds would be used to expand commercial operations, launch next-generation sequencing-based tests to diagnose pediatric genetic disorders, and build its network of disease experts.
WuXi NextCode Genomics joined Series A investors Boston Children's Hospital, Cincinnati Children's Hospital Medical Center, and Cerner.
In 2013, Claritas won a $9 million contract with the US Department of Veterans Affairs to perform exome sequencing for 19,000 veterans.
Claritas uses the NextCode Health Platform to interpret NGS results. NextCode was acquired by WuXi earlier this month.
"Our work together has the potential to transform children's healthcare, as 40 percent of pediatric disorders are understood to have a clear genetic basis today," Claritas CEO Patrice Milos said in a statement.